CryoLife reported an 11% increase in total revenues compared to Q3 2020, driven by recent product launches and strength in the U.S. On-X aortic valve business. Net income was $10.6 million, or $0.26 per share, compared to a net loss of ($2.9) million, or ($0.08) per share for the third quarter of 2020.
Total revenues increased by 11% on a GAAP basis and 9% on a non-GAAP proforma constant currency basis.
Net income was $10.6 million, or $0.26 per share.
Non-GAAP net loss was ($1.2) million, or ($0.03) per share.
Submitted PMAs to FDA for PerClot and PROACT Mitral and anticipate receiving approvals for both in 2022.
Company expects revenues for the full year to be between $296.0 and $299.0 million dollars and fourth quarter revenues are expected to be between $76.5 and $79.5 million dollars, reflecting pro forma constant currency growth of between 9.5% and 13.7% over the fourth quarter of 2019.
Analyze how earnings announcements historically affect stock price performance